Standardized SEC financial data for IONIS PHARMACEUTICALS INC — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000874015 · NASDAQ · Pharmaceutical Preparations.
Ratios for fiscal year 2025, standardized from SEC filings.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $729.3M | $810.5M | $587.4M | $787.6M | $705.1M | $943.7M |
| Cost of revenue | $11.9M | $10.8M | $14.1M | $9.1M | $11.2M | $15.9M |
| Gross profit | $717.3M | $799.6M | $573.3M | $778.5M |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $397.7M | $869.2M | $276.5M | $399.3M | $242.1M | $372.3M |
| Inventory | $22.0M | $24.8M | $22.0M | $7.4M | $12.5M | $10.0M |
| Total current assets | $2.13B | $2.35B | $2.20B | $2.64B |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $35.9M | $30.8M | -$274.4M | -$307.5M | -$500.9M | -$268.6M |
| Capital expenditures | $35.1M | $12.0M | $15.7M | $23.8M | $45.3M | $51.4M |
| Free cash flow | $772K | $18.8M | -$290.1M | -$331.3M |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/IONS/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/IONS/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $693.9M |
| $927.8M |
| R&D expense | $531.0M | $638.2M | — | $899.6M | $901.5M | $915.6M |
| SG&A expense | $354.3M | $186.3M | $150.3M | $232.6M | $267.5M | $393.9M |
| Operating income | -$172.1M | -$30.2M | -$410.2M | -$353.7M | — | -$381.7M |
| Interest expense | $9.5M | $9.3M | $8.1M | $12.7M | $17.0M | $17.3M |
| Pretax income | -$170.0M | -$29.1M | -$258.0M | -$334.0M | -$460.1M | -$379.6M |
| Income tax | $345.2M | $551K | $11.7M | $32.3M | $6.2M | $1.8M |
| Net income | -$444.5M | -$28.6M | -$269.7M | -$366.3M | — | — |
| EPS (diluted) | $-3.18 | $-0.20 | $-1.90 | $-2.56 | — | — |
Standardized from IONIS PHARMACEUTICALS INC's SEC filings — per-share figures split-adjusted. Full history via the API.
| $2.62B |
| $2.99B |
| Property, plant & equipment | $181.1M | $178.1M | $74.3M | $71.0M | $94.3M | $123.0M |
| Total assets | $2.39B | $2.61B | $2.53B | $2.99B | $3.00B | $3.52B |
| Total current liabilities | $598.9M | $240.6M | $311.6M | $448.1M | $309.3M | $781.6M |
| Long-term debt | $539.1M | — | $1.19B | $1.31B | $1.25B | $1.81B |
| Total debt | $839.6M | — | $1.19B | $1.31B | $1.25B | $2.24B |
| Total liabilities | $1.65B | $1.84B | $1.96B | $2.60B | $2.42B | $3.03B |
| Retained earnings | -$1.13B | -$1.16B | -$1.43B | -$1.80B | -$2.25B | -$2.63B |
| Total equity | $743.3M | $771.7M | $572.9M | $386.7M | $588.4M | $489.1M |
| -$546.2M |
| -$320.0M |
| Investing cash flow | $274.5M | $194.9M | -$262.6M | -$214.1M | -$134.0M | -$277.8M |
| Financing cash flow | -$596.6M | $245.9M | -$55.3M | $644.1M | $478.1M | $675.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Share repurchases | $90.5M | $0 | $0 | — | — | — |